2025 (2 POSTS)

Mease K. High safety bar, low safety margin case studies. Presented at 29th Annual Charles River Biotech Symposium, Carlsbad, CA, September 8-10, 2025.

View Abstract

Monticello TM, MacLachlan TK, Funk KA, Rock BM, Bussiere JL, Grieves JL, Schuh JCL, Henry S. 2025. Nonclinical safety assessment: An overview of drug and medical device development. Chapter 1 in: Bouchard PR, Sahota PS, Wallace S, Wojcinski ZW, Schumacher VL (eds), Toxicologic Pathology: Nonclinical Safety Assessment, 3rd edition. Boca Raton: CRC Press-Taylor and Francis Group, pp. 3-51.

2024 (2 POSTS)

Monticello TM, Potter DM, Huang Q, Hart TK, Shuey D, Troth S, Vergis JM, Tassew N, et al. 2024. Do longer duration nonclinical toxicology studies provide predictive clinical safety value? The IQ Consortium longer duration nonclinical to clinical translational database. Toxicol Appl Pharmacol 492(Sept 5):117087; doi: 10.1016/j.taap.2024.117087.

View Abstract

Petrick J, Mihalchik A, Tiwary A, Kreidl L, Swartz C, Bhattarai N. Nonclinical safety evaluation of 1-monoacetin and 2-monoacetin as potential impurities in pharmaceutical excipients. Abstract 3107, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.

View Abstract

2020 (1 POST)

Fryzek J, Bylsma L, Mease K, Movva N, Welsh BT, Wood M. 2020. Critical insights into nonclinical toxicology and real-world evidence essential for a successful rare disease product launch. EpidStrategies, Inc. White Paper.

View Abstract

2019 (1 POST)

Bussiere JL, Davies R, Dean C, Xu C, Kim KH, Vargas HM, Chellman GJ, Balasubramanian G, Monticello TM. 2019. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmacol 106(Aug):224-238; doi: 10.1016/j.yrtph.2019.05.013.

View Abstract

2018 (1 POST)

Monticello TM, Bussiere JL. 2018. Nonclinical safety evaluation of drugs. Chapter 2 in: Sahota PS, Popp JA, Hardisty JF, Gopinath C. (eds), Toxicologic Pathology: Nonclinical Safety Assessment, 2nd edition. Boca Raton: CRC Press-Taylor and Francis Group, pp. 27-64.

2017 (1 POST)

Monticello TM, Jones TW, Dambach DM, Potter DM, Bolt MW, Liu M, Keller DA, Hart TK, et al. 2017. Current nonclinical testing paradigm enables safe entry to First-in-Human clinical trials: The IQ consortium nonclinical translational database. Toxicol Appl Pharmacol 334(Nov 1):100-109; doi: 10.1016/j.taap.2017.09.006.

View Abstract

2012 (1 POST)

Monticello TM, Bussiere JL. 2012. Nonclinical safety evaluation of drugs. Chapter 2 in: Sahota PS, Popp JA, Hardisty JF, Gopinath C. (eds), Toxicologic Pathology: Nonclinical Safety Assessment. Boca Raton: CRC Press-Taylor and Francis Group, pp. 25-54.